Suchen
Eupraxia Pharmaceuticals Inc
EPRXZur Watchlist hinzufügen
8.580USD
+0.200+2.39%
Handelsschluss 09-18 16:00（ET）
560.46MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Eupraxia Pharmaceuticals Inc Unternehmen
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Eupraxia Pharmaceuticals Inc Profil
BörsenkürzelEPRX
Name des UnternehmensEupraxia Pharmaceuticals Inc
IPO-datumMar 09, 2021
CEOHelliwell (James A)
Anzahl der mitarbeiter33
WertpapierartOrdinary Share
GeschäftsjahresendeMar 09
Addresse201-2067 Cadboro Bay Rd.
StadtVICTORIA
BörseNASDAQ OMX - NASDAQ BASIC
LandCanada
PostleitzahlV8R 5G4
Telefon12505903968
Websitehttps://eupraxiapharma.com/home/default.aspx
BörsenkürzelEPRX
IPO-datumMar 09, 2021
CEOHelliwell (James A)
Führungskräfte von Eupraxia Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
228.23K
+1.47%
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
100.00K
--
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
100.00K
--
Ms. Amy Pott
Ms. Amy Pott
Director
Director
--
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Director
Director
--
--
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Director
Director
--
--
Dr. James A. Helliwell, M.D.
Dr. James A. Helliwell, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Simon Pimstone, M.D., Ph.D.
Dr. Simon Pimstone, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Richard M. Glickman
Dr. Richard M. Glickman
Independent Director
Independent Director
--
--
Mr. Paul Geyer
Mr. Paul Geyer
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
228.23K
+1.47%
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
100.00K
--
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
100.00K
--
Ms. Amy Pott
Ms. Amy Pott
Director
Director
--
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Director
Director
--
--
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Director
Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Eupraxia Pharmaceuticals Inc?
Die fünf größten Anteilseigner von Eupraxia Pharmaceuticals Inc sind: Dr. Michael Wilmink, M.D.
Wie viele Institutionen halten Anteile an Eupraxia Pharmaceuticals Inc (EPRX)?
Mit Stand vom 2026Q1 halten 56 Institutionen Anteile an Eupraxia Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 19.60M, was 32.43% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 818141.00 gestiegen.